Neurological Disease

AMPA receptor modulator-11 (example 210) is a positive allosteric AMPA receptor modulator. AMPA receptor modulator-11 can be used for research on depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD).

Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril exhibits antihypertensive and neuroprotective effects^-.

Sofpironium-¹³C,d₃ bromide (BBI 4000-¹³C,d₃) is the deuterium and ¹³C-labeled Sofpironium bromide (HY-109013). Sofpironium bromide (BBI 4000) is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium bromide reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium bromide also has a high afnity for the M1, M2, M4 and M5 subtypes.

Methylclonazepam is a benzodiazepine with anxiolytic activity. Methylclonazepam inhibits the absorption of 5-hydroxytryptamine by Schistosoma mansoni. Methylclonazepam derivatives have anti-Schistosoma mansoni activity.

Galanthamine-O-methyl-d₃ is the deuterium labeled Galanthamine. Galanthamine is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 500 nM.

(R,S)-3,4-Dicarboxyphenylglycine ((RS)-3,4-DCPG) is an AMPA receptor antagonist. (R,S)-3,4-Dicarboxyphenylglycine antagonizes AMPA-mediated depolarization of motor neurons in neonatal rats. (R,S)-3,4-Dicarboxyphenylglycine can be used in the study of neurological diseases.

TDO-IN-3 (compound 20) is an IDO1/TDO inhibitor with IC₅₀ values of 4.12 and 0.12 μM, respectively.

Icopezil (CP-118954) is an orally active, selective AchE inhibitor with an IC₅₀ of 0.33 nM. Icopezil increases acetylcholine levels in the brain and striatum of mammals, induces centrally mediated tremors and peripherally mediated salivation, and improves working memory performance in aged dogs. Icopezil serves as a parent compound for radioiodine-labeled acetylcholinesterase imaging agents. Icopezil is applicable to research related to Alzheimer's disease.

LY393615 (NCC1048) is a novel neuronal Ca²⁺ (calcium channel) and Na ⁺ channel (sodium channel) blocker with IC₅₀s of 1.9 μΜ and 5.2 μΜ for α1A and α1B calcium channel subunits. LY393615 has good brain penetration and neuroprotective effects in models of in cerebral ischemia that can be used for neurological disease research.

Dezinamide (ADD94057) is an antiepileptic agent. Dezinamide binds to the voltage-sensitive sodium channel.

β-Amyloid (1-34) is a β-Amyloid peptide consists of 34 amino acid.

BRD1652 is a highly selective GSK3 inhibitor. BRD1652 can be used in the study of emotion-related diseases.

Neurokinin Receptor (393-407), rat (SPR393–407) is a rat neurokinin 1 receptor (NK1R) fragment. NK1R is rapidly internalized by endocytosis and recycled to the plasma membrane when binding to substance P (SP). Neurokinin Receptor (393-407), rat can be used in the research of neurogenic inflammation.

SB1349 is a potent Lin28 molecular glues degrader, with DC₅₀ values of 1.594 µM and 0.777 µM for Lin28A and Lin28B, respectively. SB1349 induces proteasome-dependent degradation by directly binding and recruiting the E3 ubiquitin ligase RNF126. SB1349 can be used for the study of neuroblastoma.

(Rac)-NRL-1049 is the racemic mixture of NRL-1049 (BA-1049 (free base)) (HY-162596). NRL-1049 is an orally available and selective ROCK2 inhibitor with IC₅₀ values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations.

Viminol is a centrally acting analgesic agent. Viminol also shows antitussive activity.

Acetylleucine-d₁₀ (N-Acetyl-DL-leucine-d₁₀) is the deuterium labeled Acetylleucine (HY-B1442). Acetylleucine (N-Acetyl-DL-leucine), orally active compound, can be used for the research of acute vestibular vertigo, cerebellar ataxia and nystagmus.

TMN-OMe is a blood-brain barrier-permeable GPR39 agonist and a radiotracer for positron emission tomography (PET). TMN-OMe activates GPR39 by recruiting β-arrestin, exhibits highly selective binding ability in the mouse brain, and enables quantitative analysis of GPR39 at the in vivo level. TMN-OMe shows specific uptake in GPR39 knockout mice, Alzheimer's disease model (APP/PS1) mice, and blocking experiments. TMN-OMe facilitates in-depth exploration of changes in GPR39-related mechanisms in neurological diseases and is widely used in Alzheimer's disease research.

ICI-63197 is a phosphodiesterase 3 (PDE3) and PDE4 inhibitor with K_i values of 9 µM and 10 µM, respectively. ICI-63197 is selectivity against PDE1 and PDE2. ICI-63197 has antidepressant effects.

Synephrine (Standard) is the analytical standard of Synephrine. This product is intended for research and analytical applications. Synephrine (Oxedrine), an alkaloid, is an α-adrenergic and β-adrenergic agonist derived from the Citrus aurantium. Synephrine is a sympathomimetic compound and can be used for weight loss.